Robert Driscoll
Stock Analyst at Wedbush
(3.92)
# 1,845
Out of 5,051 analysts
396
Total ratings
40.3%
Success rate
5.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robert Driscoll
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARVN Arvinas | Reiterated: Hold | $12 | $7.45 | +61.07% | 28 | Oct 8, 2026 | |
| CGEM Cullinan Therapeutics | Reiterated: Buy | $42 | $14.95 | +180.94% | 22 | Oct 7, 2026 | |
| FHTX Foghorn Therapeutics | Downgraded: Hold | $10 → $2 | $1.95 | +2.56% | 16 | Oct 2, 2026 | |
| GLUE Monte Rosa Therapeutics | Reiterated: Buy | $37 → $27 | $10.52 | +156.65% | 13 | Oct 2, 2026 | |
| RCUS Arcus Biosciences | Reiterated: Buy | $43 | $24.34 | +76.66% | 26 | Sep 30, 2026 | |
| ACET Adicet Bio | Reiterated: Buy | $25 → $28 | $5.53 | +406.33% | 13 | Sep 29, 2026 | |
| CMPX Compass Therapeutics | Downgraded: Hold | $8 → $1 | $0.9375 | +6.67% | 5 | Sep 23, 2026 | |
| CRBP Corbus Pharmaceuticals Holdings | Reiterated: Buy | $30 | $5.27 | +469.26% | 7 | Sep 15, 2026 | |
| CBIO Crescent Biopharma | Reiterated: Buy | $27 | $14.46 | +86.72% | 7 | Sep 14, 2026 | |
| TYRA Tyra Biosciences | Reiterated: Buy | $53 | $19.60 | +170.41% | 17 | Sep 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $201 → $225 | $193.95 | +16.01% | 26 | Aug 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $60 | $36.06 | +66.39% | 27 | Aug 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $19 | $13.07 | +45.37% | 22 | Aug 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 | $2.01 | +198.51% | 3 | Aug 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $33 → $39 | $24.17 | +61.36% | 12 | Aug 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $14 | $1.77 | +690.96% | 15 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $36 | $10.40 | +246.32% | 31 | Jul 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $11 | $2.42 | +354.55% | 18 | Jun 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $80 | $63.13 | +26.72% | 4 | May 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 → $6 | $0.5931 | +911.63% | 8 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $29 → $34 | $13.24 | +156.80% | 4 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $7 → $5 | $7.26 | -31.13% | 3 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $45 → $36 | $18.15 | +98.35% | 12 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $6 → $1 | $0.9818 | +1.85% | 4 | Dec 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $4 | $2.52 | n/a | 13 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $27 | $6.87 | n/a | 1 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 → $6 | $1.22 | n/a | 14 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $8 → $1.6 | $0.365 | n/a | 10 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $67 | $150.43 | n/a | 1 | Nov 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 → $6 | $4.15 | n/a | 8 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $10.05 | n/a | 4 | Oct 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $7 → $10 | $0.0001 | n/a | 2 | Mar 19, 2020 |
Arvinas
Oct 8, 2026
Reiterated: Hold
Price Target: $12
Current: $7.45
Upside: +61.07%
Cullinan Therapeutics
Oct 7, 2026
Reiterated: Buy
Price Target: $42
Current: $14.95
Upside: +180.94%
Foghorn Therapeutics
Oct 2, 2026
Downgraded: Hold
Price Target: $10 → $2
Current: $1.95
Upside: +2.56%
Monte Rosa Therapeutics
Oct 2, 2026
Reiterated: Buy
Price Target: $37 → $27
Current: $10.52
Upside: +156.65%
Arcus Biosciences
Sep 30, 2026
Reiterated: Buy
Price Target: $43
Current: $24.34
Upside: +76.66%
Adicet Bio
Sep 29, 2026
Reiterated: Buy
Price Target: $25 → $28
Current: $5.53
Upside: +406.33%
Compass Therapeutics
Sep 23, 2026
Downgraded: Hold
Price Target: $8 → $1
Current: $0.9375
Upside: +6.67%
Corbus Pharmaceuticals Holdings
Sep 15, 2026
Reiterated: Buy
Price Target: $30
Current: $5.27
Upside: +469.26%
Crescent Biopharma
Sep 14, 2026
Reiterated: Buy
Price Target: $27
Current: $14.46
Upside: +86.72%
Tyra Biosciences
Sep 11, 2026
Reiterated: Buy
Price Target: $53
Current: $19.60
Upside: +170.41%
Aug 27, 2026
Reiterated: Buy
Price Target: $201 → $225
Current: $193.95
Upside: +16.01%
Aug 20, 2026
Reiterated: Buy
Price Target: $60
Current: $36.06
Upside: +66.39%
Aug 17, 2026
Reiterated: Buy
Price Target: $19
Current: $13.07
Upside: +45.37%
Aug 14, 2026
Reiterated: Buy
Price Target: $6
Current: $2.01
Upside: +198.51%
Aug 12, 2026
Reiterated: Buy
Price Target: $33 → $39
Current: $24.17
Upside: +61.36%
Aug 6, 2026
Reiterated: Buy
Price Target: $14
Current: $1.77
Upside: +690.96%
Jul 28, 2026
Reiterated: Buy
Price Target: $36
Current: $10.40
Upside: +246.32%
Jun 4, 2026
Reiterated: Buy
Price Target: $11
Current: $2.42
Upside: +354.55%
May 18, 2026
Reiterated: Buy
Price Target: $80
Current: $63.13
Upside: +26.72%
May 14, 2026
Reiterated: Buy
Price Target: $7 → $6
Current: $0.5931
Upside: +911.63%
May 14, 2026
Reiterated: Buy
Price Target: $29 → $34
Current: $13.24
Upside: +156.80%
May 12, 2026
Reiterated: Sell
Price Target: $7 → $5
Current: $7.26
Upside: -31.13%
May 8, 2026
Reiterated: Buy
Price Target: $45 → $36
Current: $18.15
Upside: +98.35%
Dec 19, 2025
Downgraded: Hold
Price Target: $6 → $1
Current: $0.9818
Upside: +1.85%
Aug 7, 2025
Reiterated: Hold
Price Target: $4
Current: $2.52
Upside: n/a
Jul 14, 2025
Initiated Coverage: Buy
Price Target: $27
Current: $6.87
Upside: n/a
May 8, 2025
Reiterated: Buy
Price Target: $7 → $6
Current: $1.22
Upside: n/a
Mar 20, 2025
Downgraded: Hold
Price Target: $8 → $1.6
Current: $0.365
Upside: n/a
Nov 19, 2021
Reiterated: Buy
Price Target: $67
Current: $150.43
Upside: n/a
Mar 8, 2021
Reiterated: Buy
Price Target: $7 → $6
Current: $4.15
Upside: n/a
Oct 5, 2020
Reiterated: Buy
Price Target: $8
Current: $10.05
Upside: n/a
Mar 19, 2020
Downgraded: Hold
Price Target: $7 → $10
Current: $0.0001
Upside: n/a